secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001297184-21-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q3 net revenues up 34% YoY to $112.2M; GAAP EPS $0.59 vs $0.08
------------------------------------------------------------------------

- Net revenues $112.2M (Q3 2021), up 34% from $83.4M in Q3 2020.
- GAAP net income $29.5M ($0.59 diluted EPS) vs $3.9M ($0.08) a year ago.
- Adjusted non-GAAP net income $23.0M ($0.46 EPS) vs $7.6M ($0.15).
- Growth driven by glucagon, Primatene Mist, epinephrine; CEO expects pipeline approvals in 2022.
- Nine-month net revenues $316.9M, up 25% YoY; GAAP net income $42.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718421000062/0001297184-21-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718421000062/amph-20211108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-21-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer